Department of Preventive Medicine and Public Health Laboratory Science, School of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang 212013, China.
Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, No. 42 Baiziting, Nanjing 210009, China.
Molecules. 2024 Apr 29;29(9):2050. doi: 10.3390/molecules29092050.
Deferoxamine, an iron chelator used to treat diseases caused by excess iron, has had a Food and Drug Administration-approved status for many years. A large number of studies have confirmed that deferoxamine can reduce inflammatory response and promote angiogenesis. Blood vessels play a crucial role in sustaining vital life by facilitating the delivery of immune cells, oxygen, and nutrients, as well as eliminating waste products generated during cellular metabolism. Dysfunction in blood vessels may contribute significantly to the development of life-threatening diseases. Anti-angiogenesis therapy and pro-angiogenesis/angiogenesis strategies have been frequently recommended for various diseases. Herein, we describe the mechanism by which deferoxamine promotes angiogenesis and summarize its application in chronic wounds, bone repair, and diseases of the respiratory system. Furthermore, we discuss the drug delivery system of deferoxamine for treating various diseases, providing constructive ideas and inspiration for the development of new treatment strategies.
去铁胺是一种用于治疗铁过量引起的疾病的铁螯合剂,多年来已获得美国食品和药物管理局的批准。大量研究证实,去铁胺可以减轻炎症反应并促进血管生成。血管通过促进免疫细胞、氧气和营养物质的输送以及清除细胞代谢产生的废物,在维持生命活力方面起着至关重要的作用。血管功能障碍可能会显著促进危及生命的疾病的发展。抗血管生成疗法和促血管生成/血管生成策略已被广泛推荐用于各种疾病。本文描述了去铁胺促进血管生成的机制,并总结了其在慢性创面、骨修复和呼吸系统疾病中的应用。此外,我们还讨论了去铁胺治疗各种疾病的药物传递系统,为新治疗策略的开发提供了建设性的思路和启示。